Source comparison
Tesamorelin for Women: Comparison with Alternative Therapies
Understanding where tesamorelin fits requires comparison with other peptides and medications targeting body composition. The table below contrasts mechanisms, clinical endpoints, and appropriate use cases. | Therapy | Primary Mechanism | VAT Specificity | Meta
This comparison does not assign a generated winner or score.
- Understanding where tesamorelin fits requires comparison with other peptides and medications targeting body composition. The table below contrasts mechanisms, clinical endpoints, and appropriate use cases.
- | Therapy | Primary Mechanism | VAT Specificity | Metabolic Effects | Dosing Frequency | Clinical Evidence for Women | Professional Assessment ||—|—|—|—|—|—|| Tesamorelin | GHRH receptor agonist → endogenous GH secretion | High. Preferential VAT reduction documented by CT | Improved insulin sensitivity, reduced triglycerides, no appetite suppression | Daily subcutaneous injection | FDA-approved for lipodystrophy; RCT data for metabolic syndrome | Gold standard for VAT reduction without exogenous GH; requires strict adherence || Semaglutide (GLP-1) | GLP-1 receptor agonist → delayed gastric emptying, appetite suppression | Low. Total body fat loss, not VAT-specific | Significant weight loss (10–15%), improved glycemic control | Weekly subcutaneous injection | Extensive phase III data (STEP trials) | Superior for total weight loss; does not selectively target VAT || CJC-1295/Ipamorelin | GHRH analogue + GHRP → GH secretion | Moderate. Increases GH but less VAT-specific than tesamorelin |
- Tesamorelin stands apart for its anatomical specificity. No other therapy reliably reduces visceral fat without proportional subcutaneous fat loss or total weight reduction. For women whose primary concern is metabolic risk rather than cosmetic weight loss, this distinction matters. A patient with normal BMI but elevated waist circumference and fatty liver doesn't need appetite suppression; she needs VAT mobilization.